EUDA Health Holdings Limited (EUDAW) Análise de ações

Visão geral da empresa

AUDA Health Holdings Limited (EUDAW) operates as a provider of non-invasive healthcare services with a primary operational footprint in Singapore, Malaysia, and China. The company's business model centers on offering specialized treatments such as bioenergy capsules, stem cell therapy, CRISPR gene editing services, and dietary supplements, alongside property management activities. As an entity listed with the ticker EUDAW, the firm currently employs 117 individuals, reflecting a relatively small-scale organization within the healthcare sector. The company's market capitalization and annual revenue of $5.16 million indicate that it occupies a niche position, serving a limited addressable market rather than competing as a dominant player in a broad industry. The absence of specific sector and industry classifications in public filings suggests that the company may operate across diverse verticals or within a highly fragmented niche where traditional classification standards do not apply, thereby limiting direct comparability with larger peers.

Saúde financeira

EUDA Health Holdings Limited reported a trailing twelve-month revenue of $5.16 million, yet the net income stands at a loss of $2,064,341, highlighting a significant disparity between top-line generation and bottom-line profitability. This gap reveals a cost structure where operating expenses, likely including R&D for stem cell therapies and regulatory compliance costs, substantially exceed gross profits derived from the 22.4% gross margin. The company generated an EBITDA of $-1,992,526, indicating that even before interest and tax considerations, the core business operations are currently cash-burning. Free cash flow is negative at $-3,350,164, which signifies a lack of financial flexibility to fund internal growth or return capital to shareholders without external financing. The balance sheet presents a challenging liquidity picture with cash holdings of $176,584 against total debt of $2.28 million, resulting in a debt-to-equity metric that is not available due to the company's financial structure. Furthermore, the current ratio of 0.23 indicates that current assets are less than one-third of current liabilities, signaling potential short-term liquidity constraints and an inability to cover immediate obligations with existing liquid resources. Return on Assets is recorded at -63.9%, while Return on Equity is unavailable, collectively demonstrating that management has not yet achieved positive capital efficiency and is struggling to generate returns on the deployed capital base.

Avaliação de valorização

Valuation multiples for EUDA Health Holdings Limited are largely unavailable, with the trailing P/E, forward P/E, and price-to-sales ratio all listed as N/A, which typically occurs for companies reporting negative earnings or lacking consistent sales figures relative to market cap. The price-to-book ratio is recorded at -0.01, a negative figure that mathematically indicates the market price per share is below the company's net book value, suggesting the stock is trading at a discount to its accounting equity. In the absence of traditional multiples, alternative metrics like EV/EBITDA are also N/A, preventing a standard valuation comparison with profitable peers. Regarding price volatility, the 52-week high and low are both recorded at $0.03, meaning the stock is currently trading exactly at the midpoint of its annual range with zero premium or discount relative to the high. The beta value of 0.16 indicates that the stock's price movements are significantly less volatile than the broader market, exhibiting low sensitivity to general market fluctuations. This low beta suggests that the share price is driven more by company-specific factors, such as clinical trial outcomes or regulatory approvals in Singapore and China, rather than macroeconomic trends affecting the wider index.

Growth & Income

Revenue growth for the trailing twelve months is reported at 60.2%, demonstrating a rapid expansion in top-line sales, whereas earnings growth is N/A due to the company's persistent net losses. The divergence between strong revenue growth and the inability to generate earnings growth implies that the company is in an early-stage growth phase where sales volume is increasing faster than profitability can be realized. As a non-dividend payer, the company does not distribute a dividend yield or payout ratio, effectively reinvesting its limited cash flows into research and development for its bioenergy and gene editing treatments rather than providing income to shareholders. This reinvestment strategy is characteristic of pre-profitability biotech or healthcare firms seeking to scale their operations before achieving sustainable profitability. The overall growth and income profile is defined by high revenue acceleration coupled with negative earnings and no current income distribution, presenting a high-risk, high-potential-reward dynamic typical of emerging market players in the healthcare sector.